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Abstract 
PFRED a software application for the design, analysis, and visualization of antisense oligonucleotides and 
siRNA is described. The software provides an intuitive user-interface for scientists to design a library of 
siRNA or antisense oligonucleotides that target a specific gene of interest. Moreover, the tool facilitates 
the incorporation of various design criteria that have been shown to be important for stability and 
potency. PFRED has been made available as an open-source project so the code can be easily modified to 
address the future needs of the oligonucleotide research community. A compiled version is available for 
downloading at https://github.com/pfred/pfred-gui/releases as a java Jar file. The source code and the 
links for downloading the precompiled version can be found at https://github.com/pfred.
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Introduction
Over the last three decades small interfering ribonucleic acid (siRNA) and antisense 
oligonucelotides (ASO) have emerged as powerful tools to modulate the expression of genes in vivo and 
in vitro. Potential oligonucleotide therapeutics have been discovered and developed with mixed 
success[1,2]. For example, Mipomersen, Inotersen, Patisiran and Givlaari have all been approved for use 
in recent years. Mipomersen is a lipid lowering agent that targets the ApoB gene [3,4] which was 
eventually approved by the United States Food and Drug Administration (FDA) in 2013 and later 
discontinued due to adverse effects [5], Inotersen is an antisense compound targeting transthyretin (TTR) 
for the treatment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis [6], 
Patisirian was the first siRNA approved by FDA also targeting transthyretin-meidated amyloidosis [7], and 
Givlaari targets aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria a rare 
genetic condition in which patients struggle to produce heme [8]. Furthermore, the approval of 
Nusinersen for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients represents 
a historical achievement for the SMA community and a success story for the field of nucleic acids based 
therapeutics [9].
However, the development of oligonucleotide therapeutics remains challenging as they often 
have unintended off-target effects and cause non-specific hepatic and renal toxicity. Additionally, it is 
exceptionally difficult to deliver oligonucleotides to most tissue types and organs. This can result in the 
need for tissue specific delivery systems and several siRNA compounds have advanced into development 
using this paradigm; these include liposomally liver targeted ALN-RSV01 which targets RSV through the 
nucleocapsid “N” gene [10], PF-4523655 for age related macular degeneration targeting the eye through 
direct injection [11] and galNac conjugates [12] such as the late stage ALN-AT3 [13] targeting antithrombin 
for the treatment of hemophilia. The recent FDA approval of Patisiran[14] represents a first-of-its-kind 
RNA interference (RNAi) therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-
mediated (hATTR) amyloidosis in adults and the first ever FDA approval of a siRNA treatment [7].
Designing antisense oligonucleotides (ASOs) and siRNA can be logistically challenging given the many 
competing design criteria that can be incorporated into the selection of tool or therapeutic sequences. 
Design considerations may include splice variants, cross-species targeting for validation, single nucleotide 
polymorphisms (SNPs), secondary structure, undesirable motifs (e.g. toxic, poly-A, or poly-G repeats), 
complementarity with off-target sequences, intron/exon boundaries, chemical modification pattern of 
nucleotides, and predicted activity. These factors need to be weighed according to the intended use of 
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the oligonucleotide. For example, compounds designed as in vitro tools only need to be active in a single 
species, whereas it is advantageous for therapeutic oligonucleotides to be active in model organisms as 
well as patients. A number of computational tools have been developed to address different aspects of 
the design process, including OptiRNAi [15], siExplorer [16], DSIR [17], i-Score [17,18], MysiRNA-Designer 
[19], siDirect [20,21], siRNA Selection Server [22], siRNArules [23] and siRNA-Finder [24]. Additionally, 
major vendors of siRNA reagents such as Dharmacon (siDESIGN Center) [25], GeneScript (Target Finder) 
[26] and Thermo Fisher (BLOCK-iT) [27] have web based design tools available.
In the present paper we describe PFRED (PFizer RNAi Enumeration and Design tool), a client-server 
software system designed to assist with the entire oligonucleotide design process, starting with the 
specification of a target gene (Ensembl ID) and culminating in the design of siRNAs or RNase H-dependent 
antisense oligonucleotides. Sequences are chosen using bioinformatics algorithms built upon careful 
mining of the sequence-activity relationships found in public datasets as well as internal collections. The 
tool provides researchers with a user-friendly interface where the only required input is an accession 
number for the target gene and it returns a list of properties that are believed to contribute to the efficacy 
of an siRNA or ASO. These properties include human transcripts and cross-species homology, GC content, 
SNPs, intron-exon boundary, duplex thermodynamics, efficacy prediction score and off-target matches. 
An automated oligonucleotide selection procedure is available to quickly select one potential set of 
sequences with an appropriate property profile. The selection protocol can be customized by the user 
through changes of the selection cutoffs or the addition of alternate design parameters and algorithms.
Materials and Methods
PFRED is implemented using a client-server software architecture. On the client-side, the graphical 
user interface (GUI) was developed in the Java programming language and is deployed to a user’s desktop 
through Java Web Start, the user will need to have a recent version of the Java development kit setup in 
their system. Because of the cross-platform support of Java, PFRED can be run from multiple desktop 
environments such as Windows, Mac and Linux. The most CPU-intensive algorithms used in PFRED are 
implemented as Python and Perl scripts which are wrapped within a docker container that works as a web 
service hosted in an Amazon Web Service (AWS) instance and invoked remotely from the client through 
a RESTful API, also developed in Java. Beyond the performance improvements, the client-server 
architecture also greatly simplifies the integration of disparate design algorithms that often rely on 
heterogeneous third-party libraries or reference datasets. Calls to the server-side algorithms are made 
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through the PFRED java web service which uses the REST API that was developed using the Glassfish Jersey 
Java modules. New algorithms can be added to PFRED following the conventions established for the 
existing tool.
To facilitate the use of PFRED, users only need to download the latest GUI release and run it on their 
own computer; it is also possible for users to build their own private PFRED service by downloading the 
PFRED Docker repository in order to create and run the PFRED Service container following the 
documentation given at https://github.com/pfred/pfred-docker. This technique named containerization, 
facilitates cloud and server agnosticism, because the container automatically builds the needed 
environment for the PFRED back-end to work; users can also use this local service to test their own 
alternative algorithms or models, and deploy the PFRED service in a cloud environment like AWS, Azure, 
Google cloud, or on a local server. It is only required for the user to have Docker and Docker-compose 
setup in the system (see https://docs.docker.com/compose/). The current client-server architecture 
consists on an already built-in Docker Service within a publicly queryable AWS instance managed by 
Biogen, which offers a REST API for easy PFRED end-point access to all the back-end services (see 
https://github.com/pfred/pfred-rest-service for documentation on how to compile the REST source code 
and access the PFRED end-points using a browser). The PFRED GUI takes advantage of the RESTful API in 
order to access all the needed end-points for ASO and siRNA design (Schema 1 illustrates the PFRED 
architecture).
Figure 1 gives an example of the main PFRED interface showing the enumerated antisense 
sequences and data annotations related to these compounds. Oligonucleotide sequences and their 
properties can be easily visualized and analyzed in the main table. This main PFRED table provides most 
of the common spreadsheet functions such as alphanumeric sorting, column/row resizing, column 
coloring and conditional coloring. In addition, users can choose which properties are displayed in the table 
and customize the display order by drag-and-drop. To help users sift through large numbers of sequences, 
the main table supports filtering by either sequence patterns or property values. For example, a user can 
search for oligonucleotides that are conserved between human and mouse and have high predicted siRNA 
efficacy. Oligonucleotides can also be organized into different groups and then reviewed separately. 
Additional functions are also included to help users analyze their data. For example, the mathematical 
formula feature can be used to apply weights to multiple properties and summarize them into a single 
score for ranking and selection. The data can be exported as a comma separated file (CSV) and then 
imported into other applications for further analysis.
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A key element of PFRED’s functionality is its canonical representation of oligonucleotide 
structures. In a separate paper [28] we presented a monomer based notation language to represent 
complex biomolecule structures (the Hierarchical Editing Language for Macromolecules or HELM) and a 
desktop application named PME (Pfizer Macromolecule Editor) for their drawing and visualization, which 
has become an industry standard for biopolymer notations [29]. Figure 2A shows an example of HELM 
notation for a short antisense gapmer. As polymeric biomolecules, antisense oligonucleotides and siRNAs 
can be represented with HELM notation and different sequence visualization options can be created for 
specific purposes. Included within PFRED are three oligonucleotide representations, shown in Figure 2B-
D. Figure 2B shows an explicit component or monomer view of the oligonucleotide breaking it down into 
sugars, bases and linkers. A sequence view is shown in Figure 2C, using a standard notation with RNA 
(capital) and DNA (lowercase) but emphasizing “chemical modifications” through the use of the pink dots. 
For example, the sequence shown in Figure 2C has a fully phosphorothioated backbone which is denoted 
by the pink dots between the base letters. It also has three locked nucleic acids (LNAs) at the 3’ and 5’ 
ends of the compound that are distinguished by the pink dots above the letters denoting these 
nucleosides. A final block representation is shown as Figure 2D. The block representation was created to 
emphasize patterns of chemical modifications to a structure. Base modifications are shown as pink dots 
below the blocks, sugars are colored depending on their structure (e.g. LNA-yellow, 2’OMe-Blue, etc.) and 
backbones other than phosphodiesters are represented by pink connectors above the blocks.
The PFRED enumeration workflow is shown in Figure 3. Transcript IDs and sequences of a target for 
different ortholog species (human, rat, mouse, dog, chimpanzee and macaque) are retrieved from the 
public ENSEMBL database through the ENSEMBL REST API (please refer to https://rest.ensembl.org/) 
given a single transcript or gene ID. Users define a primary transcript sequence of their length of choice 
to be enumerated (Figure 3, steps 1-3). Each enumerated oligonucleotide is then aligned to the other 
selected transcripts including splice variants and ortholog transcripts using the fast memory-efficient 
short read aligner, Bowtie, against the pre-calculated Bowtie index covering all transcript sequences [30]. 
Alignment results are processed by a Python interface and the number of mismatches to each transcript 
is reported back to PFRED as properties of the oligonucleotides. Exon location and SNP information are 
also retrieved through the EnsEMBL APIs for each base position and mapped to each oligonucleotide as 
properties.
Pre-built bowtie indexes for all species are required for off-target searches. These were built by 
creating a Python interface that automatically downloads all transcripts (cDNA) and unspliced gene 
.CC-BY 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted August 25, 2020. . https://doi.org/10.1101/2020.08.25.265983doi: bioRxiv preprint 
6
sequences for any species in FASTA format using the ENSEMBL REST API which provides the advantage of 
always relying on the latest version of the ENSEMBL database. The FASTA files are written with transcript 
ID and Gene ID included in the sequence names. These FASTA files are used to build indexes for searching 
cDNA and gene off-target matches. The ENSEMBL IDs are used for post-processing the bowtie alignment 
results to calculate the number of genes that an oligonucleotide aligns to with 0, 1 and 2 mismatches, and 
to exclude the intended target from the off-target count. For siRNA, only the cDNA database is searched 
for both the guide and passenger strands. In contrast, for antisense design, only the sense sequences (or 
antisense sequence in reverse complementary direction) is searched against both the cDNA and unspliced 
gene sequence indexes for off-target hits. The number of cDNA off-target hits is then reported as an 
oligonucleotide property for 0, 1 and 2 mismatches.
Due to the cost of synthesizing and testing siRNAs and ASOs, rational design represents a critical step 
in any oligonucleotide experiment. A priori prediction of a compound’s function is a key component of 
RNAi and ASO applications to obtain effective silencing of the desired gene. Early models were based on 
empirical rules for designing functional siRNA, obtained from the experimental results of ASO and RNAi 
screening campaigns. For RNAi sequence design, Tuschl [31,32] first and later Reynolds [33] reported a 
series of guidelines for the implementation of a “point-based” scoring scheme where the presence or 
absence of key features in an siRNA duplex will lead to an increase or decrease of the final functional 
score. Several other algorithms have emerged since then [16,17,34–39] based on more sophisticated 
scoring schemes which use sequence descriptors and supervised machine learning techniques to select 
siRNAs capable of inducing effective gene silencing in cell lines. In PFRED, an algorithm for predicting siRNA 
functionality has been implemented by using diverse sets of oligonucleotide descriptors combined with a 
support vector machine (SVM) algorithm. Details of the sequence descriptors and algorithm 
implementation were previously described elsewhere [40]. Models of ASO activity have also improved 
but can be highly dependent on the length of the ASO as well as its chemical modification. Most published 
models use either sequence motif based filters [41] or computational approaches including secondary 
structure prediction [42–44], thermodynamics [45,46], machine learning [47–49] and molecular dynamics 
simulation [50], but all have reported only limited success. Here we integrated both the thermodynamics 
parameters calculated using Oligowalk [51] and the sequence motifs reported in Matveeva [41]. Using 
these parameters, a scoring scheme was derived that penalized motifs correlated with toxicity or 
promiscuity, strong inter- and intra-molecular binding energy as well as weak binders to the RNA target. 
The model was derived and tested using data from AOBase [52] including more than 500 ASOs against 46 
targets. The thermodynamic calculations were based on unmodified DNA antisense oligonucleotides and 
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therefore of limited relevance to modifications that significantly increase the melting temperature (Tm) 
of DNA/RNA duplex such as LNA.
Once all the descriptors have been calculated for each potential ASO or siRNA the design workflow 
becomes a process of selection. An example of the PFRED selection interface for siRNA design is shown in 
Figure 3, step 4. Oligonucleotide selections are made by first filtering out those compounds which align 
with: 1) known human SNPs, 2) sequence motifs associated with non-specific binding (such as polyG, 
polyT) and 3) low complexity sequences that have a high number of perfect off-target matches. An 
additional filter for ortholog transcript matches can be added depending on the experimental design 
requirement. Also, if predicted activities are available, they may be included as a selection criterion 
(models may depend on a specific oligonucleotide length or modification type). Other oligonucleotide 
properties such as number of off-target matches and diversity of location of each oligonucleotide along 
the gene sequence can be used to finalize the selection of desired compounds for a given experiment. The 
final selected compounds can then be exported in text format in preparation for synthesis or further 
analysis outside of the tool.
Conclusions
We present here an informatics platform for the design of antisense and siRNA oligonucleotides. The 
system includes a basic set of design algorithms but is extensible such that experienced developers can 
add novel or proprietary descriptors. Workflows are included which walk researchers through the process 
of identifying a target sequence and choosing the design criteria to be applied in selection of candidate 
molecules. A series of oligonucleotide visualization and plotting algorithms are included along with 
spreadsheet functions allowing data import/export, formulas, and conditional formatting. Links to the 
source code and hosted versions can be found at https://github.com/pfred.
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